The Joint Vasculitis Registry in German-speaking countries (GeVas) - a prospective, multicenter registry for the follow-up of long-term outcomes in vasculitis.

Iking-Konert, Christof; Wallmeier, Pia; Arnold, Sabrina; Adler, Sabine; de Groot, Kirsten; Hellmich, Bernhard; Hoyer, Bimba F; Holl-Ulrich, Konstanze; Ihorst, Gabriele; Kaufmann, Margit; Kötter, Ina; Müller-Ladner, Ulf; Magnus, T; Rech, Jürgen; Schubach, Fabian; Schulze-Koops, Hendrik; Venhoff, Nils; Wiech, Thorsten; Villiger, Peter and Lamprecht, Peter (2021). The Joint Vasculitis Registry in German-speaking countries (GeVas) - a prospective, multicenter registry for the follow-up of long-term outcomes in vasculitis. BMC rheumatology, 5(1), p. 40. BioMed Central 10.1186/s41927-021-00206-2

[img]
Preview
Text
PMV.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (580kB) | Preview

BACKGROUND

Vasculitides comprise a group of rare diseases which affect less than 5 in 10.000 individuals. Most types of vasculitis can become organ- and life-threatening and are characterized by chronicity, high morbidity and relapses, altogether resulting in significant morbidity and mortality. Previous studies have been either monocentric or mainly retrospective - studies with a prospective design mostly consisted of rather small cohorts of 100 to 200 patients. The aim of the Joint Vasculitis Registry in German-speaking countries (GeVas) is to record all patients who have been recently diagnosed with vasculitis or who have changed their treatment due to a relapse (inception cohort). In GeVas, data are collected prospectively in a multicenter design in Germany, Austria and Switzerland. By this approach, courses of vasculitis and their outcomes can be monitored over an extended period.

METHODS

GeVas is a prospective, web-based, multicenter, clinician-driven registry for the documentation of organ manifestations, damage, long-term progress and other outcomes of various types of vasculitis. The registry started recruiting in June 2019. As of October 2020, 14 centers have been initiated and started recruiting patients in Germany. Involvement of sites in Austria and the German-speaking counties of Switzerland is scheduled in the near future.

DISCUSSION

In June 2019, we successfully established a prospective multicenter vasculitis registry being the first of its kind in German-speaking countries. The participating centers are currently recruiting, and systematic analysis of long-term vasculitis outcomes is expected in the ensuing period.

TRIAL REGISTRATION

German Clinical Trials Register (Deutsches Register Klinischer Studien): DRKS00011866 . Registered 10 May 2019.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology, Clinical Immunology and Allergology

UniBE Contributor:

Villiger, Peter Matthias

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2520-1026

Publisher:

BioMed Central

Language:

English

Submitter:

Brigitte Isenschmid

Date Deposited:

03 Dec 2021 10:31

Last Modified:

05 Dec 2022 15:55

Publisher DOI:

10.1186/s41927-021-00206-2

PubMed ID:

34330340

Uncontrolled Keywords:

ANCA GeVas Giant cell arteritis Long term Outcome Prospective Registry Therapy Vasculitis

BORIS DOI:

10.48350/161810

URI:

https://boris.unibe.ch/id/eprint/161810

Actions (login required)

Edit item Edit item
Provide Feedback